The National Cancer Centre Singapore (NCCS) was established in 1999 to further enhance the country’s position as a preeminent center for cancer research, education and treatment in Asia Pacific. In July 2014, NCCS and Tessa Therapeutics entered into a research collaboration in the field of cellular therapy.
In June 2016, NCCS and Tessa Therapeutics expanded their research partnership with the formation of a broad strategic alliance. The alliance encompasses research, large-scale clinical trials and the development of world leading GMP manufacturing to facilitate the development, evaluation and commercialization of immune-oncology treatments for a wide range of cancers. NCCS has granted Tessa Therapeutics exclusive rights to license and commercialize all cancer immunotherapy products and technologies arising from NCCS’ immunotherapy research. NCCS is also a strategic shareholder in Tessa Therapeutics.